They also are based on recent partnerships established between the radiotherapy manufacturer and other parties, such as Proton Partners International, which agreed in April to buy and install Elekta's MR-linac system at a network of cancer centers under development in the U.K. The deal calls for the acquisition of five systems for an order value of £25 million ($34,915,950), to be installed over a three-year period.

In March, the company paired with IBM to bridge care gaps in cancer care globally, through a partnership combining Elekta’s MOSAIQ Oncology Information System and IBM’s Watson for Oncology platform. The move aims to level the radiotherapy and oncology treatment field to put care in developing nations on par with high-end markets, such as the U.S. and Western Europe.


“If we look at all cancers in terms of effective treatment and five-year survival, in a high market like the U.S. or Western Europe, we’re expecting about a fifty percent survival rate,” Andrew Wilson, vice president of Elekta’s global marketing digital portfolio, said at the time. "Standardization of oncology care means closing the oncology treatment gap for all ... But if you look at different countries with lower GDP, these are when co-statistics start to drop, and in some articulate disease areas it’s very evident of the inequality that exists across different markets.”

Back to HCB News

MRI Homepage